LES Royalty Rates and Deal Terms Surveys

Licensing Executives Society (U.S.A. and Canada) (LES) launched a broad-reaching Royalty Rates and Deal Terms survey initiative to address the elusive gaps in industry-specific deals and trends. Available for free exclusively to members only, the results of past surveys covering Life Sciences, High Technology, and Physical Sciences Royalty Rates and Deal Terms are also available to LES members at no cost. Non-Members can purchase the surveys for a fee.

2024 Life Science Sector Royalty Rates & Deal Terms Survey Results will be released in 2025!

High Technology Royalty Rates & Deal Terms Survey

Item Name	Posted By	Date Posted
2021 Royalty Rates & Deal Terms Survey Link	Administration	9/26/2022
2021 Royalty Rate & Deal Terms Executive Summary PDF (194.16 KB)	Administration	8/1/2023
2017 Royalty Rate & Deal Term Survey Link	Administration	7/31/2023
2014 Royalty Rate & Deal Term Survey Link	Administration	8/1/2023
2014 Royalty Rates & Deal Terms Executive Summary PDF (137.58 KB) [ more ] [ hide ]	Administration	1/7/2016
The 2014 High Tech Deal Terms & Royalty Rate Survey Report is the second comprehensive Deal Terms & Royalty Rate Survey undertaken for the High Tech Sector (HTS) of LES. The survey addressed major fields within the HTS, including aerospace, software, clean technology, communications, medical devices, semiconductors, consumer products, electronics, and computers. The sample size included 94 participants coming from various sizes and types of organizations. Much has changed in the world of patents and IP licensing since the last LES licensing survey in 2011, and this report analyzes the combined data of the 2011 and 2014 surveys, and explains trends in a variety of matters, such as trends about how technology types are affected in the licensing market.
2011 Royalty Rates & Deal Terms Executive Summary PDF (218.25 KB) [ more ] [ hide ]	Administration	1/7/2016
Survey Highlights -The Survey received responses from 52 companies for the period from 2008 through 2011, with a total of 228 complete deals being submitted. -The following major high technology fields were reported: aerospace, software, clean technology, communication, semiconductor, consumer products and electronics. -86% of respondents were licensors, with more than half of them entering the deal for monetary gain in addition to a strategic relationship.

Life Sciences Royalty Rates & Deal Terms Survey

Item Name	Posted By	Date Posted
2021 Royalty Rates & Deal Terms Survey Link [ more ] [ hide ]	Administration	8/30/2022
LES Life Sciences Sector Royalty Rates & Deal Terms Survey The survey went out to approximately 2,469 LES members and 17,431 non-members, resulting in a higher response rate of 6.3% compared with 5% in 2014. A total of 155 specific intellectual property deals transacted between 2014 and 2017 were analyzed. Deals of all types were submitted including sales and licenses; out-licenses and in-licenses; lump sum and running royalty; and flat and tiered loyalty. "The valuable data we've gathered through the LES Life Sciences Sector Royalty Rates & Deal Terms Survey is not available from other public and commercial sources and reveals much more insight into the dynamics of the licensing market, given that we have the unique ability to analyze and compare the transaction-level data going back to 2008," said Jack Lu, Ph.D., CFA, LES Senior Vice President of Economic Analysis and Survey, and a Partner and Chief Economist of IPMAP, LLC
2021 Royalty Rates & Deal Terms Executive Summary PDF (588.18 KB)	Administration	5/22/2022
2018 Royalty Rates & Deal Terms Executive Summary PDF (730.16 KB) [ more ] [ hide ]	Administration	5/10/2019
2018 Survey Highlights A total of 101 completed surveys were incorporated into the final Global Life Sciences Survey Report. Of those who responded, 24% were from pharmaceutical companies, 4% were from biotech companies, 21% were from academic institutions, 8% were from government, and 45% were from other organizations. Survey respondents represented 10 of the 31 Licensing Executives Society International (LESI) Societies
2018 Royalty Rate & Deal Terms Survey Link	Administration	7/31/2023
2016 Royalty Rates & Deal Terms Executive Summary PDF (581.31 KB) [ more ] [ hide ]	Administration	2/16/2017
2016 Survey Highlights A total of 117 completed surveys were incorporated into the final Global Life Sciences Survey Report. Of those who responded, 19% were from pharmaceutical companies, 12% were from biotech companies, 22% were from academic institutions, 11% were from government, and 36% were from other organizations. Survey respondents represented 8 of the 33 Licensing Executives Society International (LESI) Societies
2016 Royalty Rate & Deal Terms Survey Link	Administration	7/31/2023
2014 Royalty Rates & Deal Terms Executive Summary PDF (129.12 KB) [ more ] [ hide ]	Administration	2/16/2016
2014 Survey Highlights A total of 128 completed surveys were incorporated into the final Global Life Sciences Survey Report. Of those who responded, 16% were from pharmaceutical companies, 19% were from biotech companies, 20% were from academic institutions, 7% were from government, and 38% were from other organizations. Approximately 64% of the deals were considered “Global” in scope.
2014 Royalty Rate & Deal Term Survey Link	Administration	7/31/2023
2009 Royalty Rates & Deal Terms Executive Summary PDF (455.72 KB) [ more ] [ hide ]	Administration	2/16/2016
Survey Highlights A total of 184 completed surveys were incorporated into the final Global BioPharma Survey Report with over 40% of the reported deals from outside North America. This is a 20% increase in response from 2008. Of those who responded, 39% were from pharmaceutical companies, 23% were from biotech companies, 12% were from academic institutions, 6% were from government, and 20% were from other organizations. The survey report provides a detailed analysis on fixed royalties, tiered royalties, deal terms, valuation methods, and therapeutic areas. Over 80% of the deals submitted had licenses that included the United States and close to 63% of licenses were considered “Global” in scope. Sixty-one percent of the deals were reported by the licensors and 82% of the deals were categorized as exclusive.
2008 Royalty Rates & Deal Terms Executive Summary PDF (449.12 KB) [ more ] [ hide ]	Administration	2/16/2016
Survey Highlights Over 150 deals analyzed, involving pharmaceutical companies (28%), biotechnology companies (26%), and academic Institutions (35%). 120 deals completed in 2006 or 2007 Key Deal Terms Small Molecule compounds were included in more than 50% of all deals submitted 88% of deals were exclusive 54% of deals included a fixed royalty; 33% included tiered royalty rates 80% included an upfront payment 90% of deals included U.S. rights; 70% were worldwide 57% of products covered have estimated peak sales of less than $100M

Physical Sciences Royalty Rates & Deal Terms

Item Name	Posted By	Date Posted
2010 CEEM Royalty Rate and Deal Terms Survey Link	Administration	7/31/2023
2010 CEEM Executive Summary PDF (74.92 KB) [ more ] [ hide ]	Administration	2/16/2016
2010 Survey Highlights Survey participation included academic institutions (34%), operating companies that ranged from big energy to start-up (39%), lawyers (16%), and other licensing organizations (11%). Approximately 70% of the deals collected contained flat running royalties and most deals were entered by the licensor. About 75% of the deals were executed during 2008 or 2009 and 80% of the deals came from the chemicals and energy sectors. Of those reported, approximately 40% of the deals estimated peak annual sales of less than $50 million, most deals involved commercialized or soon to be commercialized products/technologies and a majority of the deals were exclusive.